Changeflow GovPing Pharma & Drug Safety Tricyclic Heteroaryl Compounds as Inhibitors of...
Routine Notice Added Final

Tricyclic Heteroaryl Compounds as Inhibitors of TYK2 and/or JAK1

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO published patent application US20260098044A1 for tricyclic heteroaryl compounds that inhibit TYK2 and/or JAK1 activity. The compounds are directed toward treating skin, respiratory, ophthalmic, and rectal diseases, cancer, and neuroinflammation. Inventors include Stacey Shepard, Onur Atasoylu, Song Mei, and Jun Pan, with application number 19348390 filed October 2, 2025.

What changed

The USPTO published a new patent application covering tricyclic heteroaryl compounds designed to modulate TYK2 and JAK1 kinase activity. The compounds have potential therapeutic applications in skin disorders, respiratory conditions, ophthalmic diseases, rectal disorders, oncological conditions, and neuroinflammation.

For pharmaceutical companies and researchers in kinase inhibitor development, this patent application represents potential prior art that could affect freedom-to-operate considerations for competing TYK2 or JAK1 inhibitor programs. Competitors developing similar compounds should conduct patent landscape analysis to assess potential infringement risks.

What to do next

  1. Monitor for patent prosecution updates
  2. Review claims for freedom-to-operate analysis

Archived snapshot

Apr 11, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1

Application US20260098044A1 Kind: A1 Apr 09, 2026

Inventors

Stacey Shepard, Onur Atasoylu, Song Mei, Jun Pan

Abstract

The present application provides tricyclic heteroaryl compounds that modulate the activity of the JAK1 and/or TYK2, which are useful in the treatment of various disorders and diseases, including skin, respiratory, ophthalmic, and rectal diseases and disorders, cancer, and neuroinflammation.

CPC Classifications

C07D 495/14 A61K 31/437 A61K 31/444 A61K 31/496 A61K 31/497 A61K 31/501 A61K 31/506 A61K 31/5377 C07D 519/00

Filing Date

2025-10-02

Application No.

19348390

View original document →

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260098044A1
Docket
19348390

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Drug compound research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!